SEARCH 
COMPANIES
Discover the reality of companies and brands!
TRANSNATIONALE.ORG
Free and independant information on large corporations

Novartis AG

Headquarters : Lichtstrasse 35, CH-4002 Basel Switzerland Switzerland
Job offers, investor relations : web www.novartis.com tel. 41-61-324-8000 email: kamran.tavangar@group.novartis.com stock : NVS analytics

Brands

name
click to compare prices
» Shop local, ethical and at the best price on Ethishop

« Ethical » rating of Novartis AG , group and subsidiaries

Human 1 Jobs -6% /1998 Pollution 12 Fraud 3 Offshore 13 Sales 37 Bn $.€ /year Profit 44 Bn $.€ /1998 Wage 1770 *min. Influence 13 Infocom 5
[click on the rating for the method or on the number for the data]

shareholdercountry%source
Landolt, PierreSwitzerland
» More shareholders of Novartis AG
year
business
source
2007Novartis sells 13,2% of the generic drugs bought in France.Les Echos
2006Novartis is the world's third-largest pharmaceutical group.Les Echos
2006Novartis sells 5% of the vaccines bought in the world.Les Echos
2006Europe's third-largest drugmakerBloomberg
2004Novartis sells 11% of the tobacco substitutes bought in FranceLes Echos
2004Novartis is the largest generic drug maker in the world.
subsidiarycountry%source
Alcon Lab. Inc. United States of America100Le Monde
Altus Food Co. United States of America50
Azupharma Germany100
Biochemie Group Switzerland100
Chiron Corp United States of America100New York Times
Geneva Pharmaceuticals United States of America100
Genevar France100
Hexal AG Germany100Les Echos
Lab. Normal Produtos Farma. Portugal100
Multipharma Netherlands100
Roche Holding Switzerland20Les Echos
Rolab 100
Servipharm Switzerland100
Syngenta AG Switzerland61
» More subsidiaries of Novartis AG
country
address & contact : production type
incentive source
Netherland Antilles Netherland Antilles
Novartis Investment NV, Curacao :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Argentina Argentina
Buenos Aires :
 
Bangladesh Bangladesh
Dhaka :
 
Bermuda Bermuda
Novartis International Pharmaceutical Ltd., Hamilton :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Bermuda Bermuda
Triangle International Reinsurance Ltd., Hamilton :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Brazil Brazil
Novartis Seeds Limitada, Sao Paulo :
 
Chile Chile
Novartis Chile SA, Santiago :
 
China China
Zhejiang Tianyuan (85%) : Production, vaccins dont un vaccin contre la fièvre hémorragique avec syndrome rénal (HFRS).
 Les Echos
China China
Novartis' 8th global research center :
 
China China
Shangai Novartis Nutricion Ltd. :
 
China China
Beijing Novartis Pharma Ltd. Beijing :
 
Colombia Colombia
Novartis de Colombia, Santafé :
 
Costa Rica Costa Rica
Productos Gerber de Centroamerica SA, San José :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Côte d'Ivoire Côte d'Ivoire
Sochim, Abidjan :
 
Egypt Egypt
Novartis Pharma SAE, Cairo :
 
Guatemala Guatemala
:
 
Hong-Kong Hong-Kong
Novartis Agro Ltd. :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Hungary Hungary
Novartis Seeds Kft. Budapest :
 
British Virgin Islands British Virgin Islands
Novartis Overseas Finance Ltd., Road Town Tortola :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
British Virgin Islands British Virgin Islands
Novartis Capital Ltd., Road Town Tortola :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
India India
: Statistics
 Time
India India
Novartis Entreprises, Mumbai :
 
India India
Novartis India Ltd., Mumbai :
 
Indonesia Indonesia
PT Novartis Biochemie, Jakarta :
 
Indonesia Indonesia
PT Ciba Vision Batam :
 
Ireland Ireland
Dublin : R&D
Offshore finance, secret bank account, tax haven, shell companies or free zone(s) Les Echos
Ireland Ireland
Waterford : R&D
Offshore finance, secret bank account, tax haven, shell companies or free zone(s) Les Echos
Kenya Kenya
:
 
Mexico Mexico
Ciba, JALISCO CHAPALA GUADALAJARA - OCOTLAN KM 4.5 & 373 70650 :
 Sistema de Informacion de la Industria Maquiladora
Mexico Mexico
CARR. MEX-TLAX. 5000 LAS FABRICAS N/D PUEBLA PUEBLA & 481199 :
 Sistema de Informacion de la Industria Maquiladora
Mexico Mexico
DISTRITO FEDERAL COYOACAN TLALPAN 3058 STA. URSULA COAPA & 4226340 :
 Sistema de Informacion de la Industria Maquiladora
Nigeria Nigeria
:
 
Pakistan Pakistan
Novartis Pharma Ltd. Karachi :
 
Panama Panama
:
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Philippines Philippines
Novartis Nutricion Philippines Inc. Pasig/Manila :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Philippines Philippines
Novartis Healthcare Philippines Inc., Makati/Manila :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Philippines Philippines
Novartis Agro Philippines Inc., Makati/Manila :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Poland Poland
Alima/Gerber SA Warsaw :
 
Dominican Republic Dominican Republic
:
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Singapore Singapore
Novartis Crop Protection Pte Ltd. :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Slovenia Slovenia
Lek :
 Les Echos
Switzerland Switzerland
:
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Thailand Thailand
Novartis Nutricion Ltd. :
 
Turkey Turkey
Novartis Saglik, Istanbul :
 
Turkey Turkey
Ciba-Geigy :
 US Government Country Business Profile
Uruguay Uruguay
Novartis Uruguay SA, Montevideo :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Venezuela Venezuela
Novartis Nutricion de Venezuela SA, Caracas :
 
Vietnam Vietnam
Novartis Ltd. Bien Hoa City :
 

year name
photo position; compensation
source
2006Vasella, Daniel
See the photo of: Vasella, Daniel Chief Executive Officer; salary: 2,72 million US$;
2004Vasella, Daniel
See the photo of: Vasella, Daniel Chief Executive Officer; salary: 13,59 million Eu€;
AGEFI
2000Kindler, Hans
See the photo of: Kindler, Hans Executive committee;
Corporate Europe Observatory
1999Breuel, Birgit
See the photo of: Breuel, Birgit Director;
1999Burckhardt, Peter
See the photo of: Burckhardt, Peter Director;
1999Doerig, Hans-Ulrich
See the photo of: Doerig, Hans-Ulrich Director;
1999Frehner, Walter G
See the photo of: Frehner, Walter G Director;
1999Genillard, Robert L
See the photo of: Genillard, Robert L Director;
1999George, William W
See the photo of: George, William W Director;
1999Jetzer, Alexandre F
See the photo of: Jetzer, Alexandre F Director;
1999Landolt, Pierre
See the photo of: Landolt, Pierre Director;
1999Lippuner, Heini
See the photo of: Lippuner, Heini Director;
1999Rudloff, Hans-Jorg
See the photo of: Rudloff, Hans-Jorg Director;
1999Sihler, Helmut
See the photo of: Sihler, Helmut Director;
1999Vasella, Daniel
See the photo of: Vasella, Daniel Chief Executive Officer;
1999Wander, Jean
See the photo of: Wander, Jean Director;
1999Zinkernagel, Rolf M
See the photo of: Zinkernagel, Rolf M Director;
year
employees
<>
social impact : country
source
2008
96917
Les Echos
2008
-550
Internal restructuring: Novartis changes the management of three of four business units and is cutting 550 jobs in U.S. marketing.: United States of America
Bloomberg
2008
-2500
Internal restructuring: Novartis cuts 2500 jobs to save 1,6 billion dollars per year after 2008. Four drugs are competed by generic drugs and a fifth one was withdrawn because of dangerous side effects.:
Les Echos
2007
98788
Les Echos
2007
-1300
Internal restructuring: Novartis removes medical representatives jobs in the United States.: United States of America
Les Echos
2006
100735
Les Echos
2005
Douze employées ou ex-employées de Novartis ont porté plainte à New York contre le groupe suisse. Elles l'accusent de discriminer sexiste, en matière de salaires, de qualifications, de promotions, de formation continue et de pratiques disciplinaires. Elles réclament 100 millions de dollars de dédommagement. Novartis a réfuté les accusations portées à son encontre.: United States of America
Tsr.ch
2004
Le tribunal de grande instance condamne Novartis à retirer certaines dispositions de son code de conduite à l'usage de ses employés: France
Les Barons Marqués
2003
78541
2002
73000
2001
71116
1999
-1100
AP
1999
81854
1998
82449
1997
87239
1996
116178
1995
133959
1989
-150
Canadian Labour Congress
year
employees
<>
social impact : country
source
 18 informations, access to subscribers
year
country : consequences
source
2007France : Between 1950 and 1960, Novartis and other chemical industries of Basle illegally discarded 600 tons of nitrobenzine and other dyes synthesis products. The site was discovered by chance by a farmer of Hagenthal-le-bas.Les Echos
2005United States of America brand: Trileptal : Serious skin reactions including skin disorders called toxic epidermal necrolysis and Stevens-Johnson syndrome.Reuters
2005brand: Clozaril : Older patients with dementia who are given antipsychotic medicines are far more likely to die prematurely than those given placebos. Most died of heart-related problems like heart failure or infections like pneumonia (FDA).New York Times
2004 : Stockage de 150 000 tonnes de déchets chimiques à Bonfol entre 1961 et 1976 à dix mètres de profondeur, sur une superficie de 20.000 m2.AFP
2002France : Production, purchase or sale of genetically modified organisms which may cause an irreversible genetic pollution, a destruction of the biodiversity and health risks for the consumers.UFC Que Choisir
2001United States of America : ClonageWall Street Journal Europe
2000 : ExplosionSwissinfos
1999brand: Céréal : Risque alimentaire (OGM)UFC Que Choisir
1986France : Sandoz, pollution du Rhin
  : Production, purchase or sale of genetically modified organisms which may cause an irreversible genetic pollution, a destruction of the biodiversity and health risks for the consumers.The Guardian
year
country : consequences
source
 10 informations, access to subscribers
year
country : description
2004South Korea : Le glivec permet de maintenir en vie les patients atteints par la leucemie myeloïde. Prix du traitement: 55000 euros/an. Le glivec a été développé largement grâce à des financements publicsArte

  • Subsidy

yearfinancial misdemeanorsalesincome buybacksource
2006   36,755,26   billion US$
2005   32,535,19   billion US$
2005 Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said.     Canadian Press
2005   2,567billion Eu€Le Point
2004   28,255,77 0,675billion Eu€La Tribune
2003   24,865,02   billion Eu€
2002   23,155,22   billion US$
2001   19,344,24   billion US$
2000   17,473,91   billion US$
1999   18,714,94   billion US$
1999   2,4billion US$AP
1998   17,24,46   billion US$
yearfinancial misdemeanorsalesincomeassetsbuybacksource
 12 informations, access to subscribers
year
purpose : intermediary/lobby : institution
source
2004Avoid compulsory licensing of the glivec : : Secretary of State translateArte
2001Access to foreign market (through MAI, WTO, GATS), prevent binding environmental regulations : USCIB (US Council For International Business) : : US Government translateUSCIB
2000Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate translateWashington Post
2000Prevent binding environmental regulations (environmental protection through economic growth, self-regulation and free trade) : WBCSD (World Business Council for Sustainable Development) : : United Nations translateCorporate Europe Observatory
2000Lift the ban on bovine growth hormons, the moratorium on GMOs : EFPIA (European Federation of Pharmaceutical Industry Associations) : : European Commission translateEFPIA
2000Market access (through WTO), cheaper energy (through energy liberalization in Europe); uniform rules to enable the patenting of plants and animals (through TRIPS); prevent advert legislation on chemicals, self-regulation instead; : CEFIC (European Chemical Industry Council) : : European Commission translateCorporate Europe Observatory
2000lift the ban on bovine growth hormon : FEDESA : : European Commission translateFedesa
1999Market access and investment protection (through WTO, GATS), avoid social and environmental rules : ICC (International Chamber of Commerce) : : WTO, GATS translateCorporate Europe Observatory
1999Market admission for genetically modified organisms : EuropaBio : : European Commission translateCorporate Europe Observatory
1998Regulation favorable to company's interests : Contribution to Candidate's Political Action Committee : amount: 156 thousand US$ : US President, Congress, Senate translateCenter for Responsive Politics
1998Regulation favorable to company's interests : Contribution to Candidate's Political Action Committee : amount: 15 thousand US$ : US President, Congress, Senate translateCenter for Responsive Politics
» More influence from Novartis AG
» Influence in 2007
year
purpose : intermediary/lobby : institution
source
 11 informations, access to subscribers
» More influence from Novartis AG
» Influence in 2007
year
dubious practice : image
source
2006Biopiracy - Appropriation of public knowledge: Novartis sues India to prevent it from producing a generic version of its drug, in spite of the international authorization of the agreements on the intellectual property (TRIPS).: AFP
2005Disinformation: Estradot, an estrogen patch for women made by drug industry giant Novartis, has been promoted in Australia by a fake news package including a press release, a video news release (VNR) and an audio news release (ANR). The VNR was used without attribution by Channel 7 News. MediaWatch presenter, Liz Jackson, reported that "on radio it was everywhere, over and over again, using only the medical experts the PR company provided." Potential side effects, Jackson reported, were "almost completely ignored by the media, except when one of the company's experts raised it herself to dismiss lingering concerns.: ABC
2004Arguable partnership: Alliance globale pour le développement de médicament contre la tuberculose (TB Alliance), Singapoure: value: humanitaire; Les Barons Marqués
2001ad budget: 306 million US$; Advertising Age
2000ad budget: 324 million US$; Advertising Age
2000Arguable partnership: Global Compact with the United Nations: value: Respects human, social and environmental laws; ONU
1999slogan: Maalox, on vit vraiment mieux sans brulures d'estomac.;
1998ad budget: 335 million US$; Advertising Age
1997ad budget: 350 million US$; Advertising Age
1990slogan: Win the instar wars. Javelin by Sandozcrop protection.;


Bookmark and Share    en español  en français  in italiano
translate this page in arabic chinese dutch german japanese korean russian
Legal notice © T&C 1999-2010
 CONTRIBUTIONS